Drug prices have lost their headline appeal. That has got to be a relief to pharma execs who have pipeline problems and patent expirations to deal with and don't need to be worried about bad publicity egging on Congress to price-control schemes. But there are new threats to drug prices brewing - and one of them is industry's old nemesis: government rebates.
Cole Werble
The headline appeal of drug prices has suddenly disappeared.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
